Navigation Links
Debiopharm Group™ and Aurigene Nominate Development Candidate
Date:9/13/2010

y science at Aurigene. It also paves the way for a larger synergistic alliance between the companies," added CSN Murthy, CEO of Aurigene.

About Debiopharm Group™ Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III. Debiopharm is also prepared to consider earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Besides drug development, Debiopharm Group has recently embarked in the field of companion diagnostics with a view to progressing in the area of personalised medicine.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information on Debiopharm Group™, please visit: www.debiopharm.com.

About AurigeneEstablished in Bangalore, India, in 2002, Aurigene Discovery Technologies Ltd. is a drug discovery biotech focused on small molecule and peptide drug discovery. With proprietary Structural Biology and Fragment-based Drug Design technology platforms, and experienced scientific leadership, Aurigene is a fully integrated Drug Discovery company focused on small molecule and peptide drug discovery and development from target identification and validation to pre-IND drug candidates in oncology, metabolic disorders, autoimmune diseases and anti-infectives.. Aurigene has- a proven track record of successful partnerships with big and medium-sized pharma and biotech companies globally. Auri
'/>"/>

SOURCE Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025
2. The Japanese Cancer Association and Debiopharm Group Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research
3. Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930
4. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
5. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
6. Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries
7. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
8. Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients
9. Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment
10. Sinovacs CEO Weidong Yin Nominated for China Central Televisions Prestigious Economic Man-of-the-Year Award
11. Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- Scott Steiger lives in St. Louis ... engineer for the past 20 years, he,s traveled extensively and prior ... been to six of the seven continents. Travel is a big ... Photo - http://photos.prnewswire.com/prnh/20141126/161077 So when ... good idea of what,s required. His latest creation is ...
(Date:11/26/2014)... -- Zynerba Pharmaceuticals , Inc., a specialty pharmaceutical ... cannabinoid treatments, today announced that the company will present ... The conference will be held December 2 to 3, ... York . Zynerba,s Chairman and CEO, Armando ... December 2. To listen to a webcast ...
(Date:11/26/2014)... 26, 2014 The medical magnetic resonance ... of 4%, with world market revenues for 2013 ... and other types of medical imaging have led ... numerous medical conditions in children and adults, each ... report, Medical Imaging Markets , analyzes the ...
Breaking Medicine Technology:Steiger Has Created the First Pill Case Specifically Designed For Travel 2Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
... (ERT), (Nasdaq: ERT ) a global ... to biopharmaceutical and healthcare organizations and the market leader ... in drug development, announced today results for the ... noted, all comparative numbers refer to changes from ...
... MOUNTAIN VIEW, Calif., Aug. 1, 2011 VIVUS, Inc. ... development and commercialization of novel therapeutic products, today reported its financial ... 2011. Second Quarter ResultsFor the second quarter ... million, or $0.20 per share, as compared to a net loss ...
Cached Medicine Technology:ERT Reports Second Quarter 2011 Operating Results 2ERT Reports Second Quarter 2011 Operating Results 3ERT Reports Second Quarter 2011 Operating Results 4ERT Reports Second Quarter 2011 Operating Results 5ERT Reports Second Quarter 2011 Operating Results 6ERT Reports Second Quarter 2011 Operating Results 7ERT Reports Second Quarter 2011 Operating Results 8ERT Reports Second Quarter 2011 Operating Results 9ERT Reports Second Quarter 2011 Operating Results 10ERT Reports Second Quarter 2011 Operating Results 11ERT Reports Second Quarter 2011 Operating Results 12ERT Reports Second Quarter 2011 Operating Results 13VIVUS Reports Second Quarter and First Six Months 2011 Financial Results 2VIVUS Reports Second Quarter and First Six Months 2011 Financial Results 3VIVUS Reports Second Quarter and First Six Months 2011 Financial Results 4VIVUS Reports Second Quarter and First Six Months 2011 Financial Results 5VIVUS Reports Second Quarter and First Six Months 2011 Financial Results 6VIVUS Reports Second Quarter and First Six Months 2011 Financial Results 7
(Date:11/27/2014)... November 27, 2014 The founders of VIM ... comfortable and high functioning compression socks, are proud to announce ... use an innovative Gradient Pressure (TM) knitting technology that is ... VIM & VIGR’s commitment to adding flair and style to ... functional recently caught the eye of a writer at ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 Two international ... implants procedure will help one person with significant ... Dr. Saj Jivraj and Dr. Mamaly Reshad of the ... Calif., have launched a website devoted to helping dentist ... of the website would be devoted to helping a ...
(Date:11/27/2014)... California (PRWEB) November 27, 2014 Developers and ... a new plugin entitled ProPip, taking FCPX to the next ... picture effect with a few clicks of a mouse,” said ... time saver that our users will appreciate.” , With ProPip ... customization leaving the possibilities truly endless. ProPip is great for ...
(Date:11/27/2014)... Philadelphia, PA (PRWEB) November 27, 2014 ... alongside volunteer Aria Health employees, prepared and donated ... to the Lutheran Settlement House , a non-profit, ... and families living in Philadelphia. The dinners were ... Settlement House Senior Center, and distributed to vulnerable ...
(Date:11/27/2014)... India (PRWEB) November 27, 2014 ... announced a search engine optimization service just at ... businesses or start-ups cannot afford costly search engine ... service package, keeping their affordablity and requirements into ... service cost, but it has not compromised with ...
Breaking Medicine News(10 mins):Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Aria Health Prepares and Donates 200 Thanksgiving Dinners 2Health News:RBSEO Services Announces SEO Services at $99 Only 2
... Alan Mozes HealthDay Reporter , SATURDAY, Dec. 4 ... be an effective, convenient and safer treatment for patients coping ... According to the research, published online Dec. 4 in ... could offer a new option for these potentially life-threatening ...
... 3 (HealthDay News) -- Use of androgen suppression therapy ... receiving lower Medicare payments for the treatment, but use ... stayed steady, a new study shows. The findings, ... the National Cancer Institute , suggest the payment cuts ...
... standards for outcome reporting in breast reconstruction are needed, ... The Journal of the National Cancer Institute. ... to 40% of women with breast cancer undergo a ... decision-making is information from health professionals. However, that information ...
... FRIDAY, Dec. 3 (HealthDay News) -- New research explains why immune ... drug-resistant HIV. In those cases, the virus has mutations that ... to kill immune cells, explained the researchers at the Mayo Clinic ... that not all HIV is equally bad for the immune system, ...
... a new standard treatment for Breast Cancer at early ... 0 funded by Spanish Breast Cancer Research Group (GEICAM) ... thousand patients and 50 hospitals participated in the study, ... The New England Journal of Medicine. Results indicate that ...
... 3 (HealthDay News) -- A protein that regulates prostate stem ... of healthy cells into prostate cancer cells has been identified ... protein, could prove important in efforts to find ways to ... from the University of California, Los Angeles. Previous research ...
Cached Medicine News:Health News:New Blood Thinner May Help Fight Dangerous Leg Clots 2Health News:New Blood Thinner May Help Fight Dangerous Leg Clots 3Health News:Medicare Cuts May Have Spurred Drop in Prostate Cancer Treatment 2Health News:Improvement needed for mastectomy outcome reporting 2Health News:Spanish Oncology to establish a new standard treatment on breast cancer at early stages 2Health News:Spanish Oncology to establish a new standard treatment on breast cancer at early stages 3
Double-ended. 3 mm round semi sharp end and 2.75 mm elevator end. Angled 45 degrees....
Double-ended. Designated most popular model or size....
2 mm tip....
Heavy. 7.5 mm curved tip....
Medicine Products: